FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308139049> ?p ?o ?g. }

• W4308139049 endingPage "A504" @default.
• W4308139049 startingPage "A503" @default.
• W4308139049 abstract "Abstract Objective We previously reported that Neuromedin B (NMB) is expressed in murine pituitary corticotrophs under adrenal insufficiency (1). Because NMB is also expressed in several cancer cells and stimulates ACTH secretion, we hypothesized that NMB is related to corticotroph adenoma cell proliferation and hormone secretion. To examine this hypothesis, we investigated the effects of a NMB receptor (NMBR) antagonist on AtT-20 cells, a tumor xenograft model and patient-derived corticotroph adenoma cells. Methods 1. NMB and NMBR expression in human pituitary adenoma: We performed real-time qPCR and immunostaining on human pathological specimens of corticotroph and non-functioning pituitary adenomas to investigate NMB and NMBR expression. 2. Experiments in AtT-20 cells: We extracted RNAs, proteins and mediums from AtT-20 cells after incubation with NMBR antagonist PD168368, and performed real-time qPCR, western blotting and ELISA analyses. We also performed WST-1 assay to investigate cell proliferation. 3. Experiments in a tumor xenograft model: AtT-20 cells in Matrigel were injected subcutaneously into BALB/c-nu mice. A week after inoculation, we administered 1.2 mg/kg PD168368 intraperitoneally once daily for 14 days. Upon completion of treatment, tumors were measured and cardiac blood was collected. 4. Experiments in patient-derived corticotroph adenoma cells: We isolated surgically resected human corticotroph adenoma cells from patients who underwent trans-sphenoidal surgery and investigated mRNA expression and medium ACTH secretion after incubation with PD168368. Statistical analysis: Comparisons between two groups were made by unpaired Student t test. Multiple groups were compared using one-way ANOVA followed by Dunnett's test for comparison with control group. Statistical significance was defined as p &lt; 0. 05. Results 1. NMB and NMBR expression levels were significantly higher in human corticotroph adenomas (13 and 33 times higher, respectively) than in non-functioning adenomas in the qPCR analyses. Immunostaining confirmed higher expression of NMB and NMBR in corticotroph adenoma. 2. Treatment with 100 nM PD168368 significantly suppressed Pomc mRNA and protein expression in AtT-20 cells by 22% and 25% respectively compared control group. Medium ACTH secretion, mRNA and protein expression of cyclin E1 and cell proliferation were also suppressed by PD168368. 3. Mice treated with PD168368 had significantly lower tumor growth rate, plasma ACTH and corticosterone than control group (70 vs 161%, 97 vs 180 pg/ml, 813 vs 1045 ng/ml, respectively). 4. Treatment with PD168368 significantly suppressed POMC mRNA expression (12-31%) in 4 out of 6 patient-derived corticotroph adenoma cells. Medium ACTH secretion was also suppressed (14-53%) in 3 out of 4 cases which could be evaluated. Cyclin E mRNA expression were also suppressed in 3 out of 4 cases in which POMC mRNA expression were suppressed. Conclusions NMBR antagonist may represent a potential treatment for Cushing disease, which effect may be mediated by decreased cyclin E expression. Reference: (1) Kameda H et al., Endocrinology 2014;155(7): 2492–9. Presentation: No date and time listed" @default.
• W4308139049 created "2022-11-08" @default.
• W4308139049 creator A5006626284 @default.
• W4308139049 creator A5032820934 @default.
• W4308139049 creator A5046867279 @default.
• W4308139049 creator A5055696290 @default.
• W4308139049 creator A5060578424 @default.
• W4308139049 creator A5073112205 @default.
• W4308139049 creator A5073763025 @default.
• W4308139049 creator A5078843127 @default.
• W4308139049 creator A5079071350 @default.
• W4308139049 date "2022-11-01" @default.
• W4308139049 modified "2023-09-24" @default.
• W4308139049 title "ODP338 Neuromedin B Receptor Antagonist Suppresses ACTH Secretion and Cell Proliferation in Human and Mouse Corticotroph Adenoma" @default.
• W4308139049 doi "https://doi.org/10.1210/jendso/bvac150.1047" @default.
• W4308139049 hasPublicationYear "2022" @default.
• W4308139049 type Work @default.
• W4308139049 citedByCount "0" @default.
• W4308139049 crossrefType "journal-article" @default.
• W4308139049 hasAuthorship W4308139049A5006626284 @default.
• W4308139049 hasAuthorship W4308139049A5032820934 @default.
• W4308139049 hasAuthorship W4308139049A5046867279 @default.
• W4308139049 hasAuthorship W4308139049A5055696290 @default.
• W4308139049 hasAuthorship W4308139049A5060578424 @default.
• W4308139049 hasAuthorship W4308139049A5073112205 @default.
• W4308139049 hasAuthorship W4308139049A5073763025 @default.
• W4308139049 hasAuthorship W4308139049A5078843127 @default.
• W4308139049 hasAuthorship W4308139049A5079071350 @default.
• W4308139049 hasBestOaLocation W43081390491 @default.
• W4308139049 hasConcept C126322002 @default.
• W4308139049 hasConcept C134018914 @default.
• W4308139049 hasConcept C170493617 @default.
• W4308139049 hasConcept C185592680 @default.
• W4308139049 hasConcept C2777428134 @default.
• W4308139049 hasConcept C2777658017 @default.
• W4308139049 hasConcept C2779029589 @default.
• W4308139049 hasConcept C2779318953 @default.
• W4308139049 hasConcept C2780546910 @default.
• W4308139049 hasConcept C71315377 @default.
• W4308139049 hasConcept C71924100 @default.
• W4308139049 hasConcept C79381400 @default.
• W4308139049 hasConcept C86803240 @default.
• W4308139049 hasConcept C94984642 @default.
• W4308139049 hasConceptScore W4308139049C126322002 @default.
• W4308139049 hasConceptScore W4308139049C134018914 @default.
• W4308139049 hasConceptScore W4308139049C170493617 @default.
• W4308139049 hasConceptScore W4308139049C185592680 @default.
• W4308139049 hasConceptScore W4308139049C2777428134 @default.
• W4308139049 hasConceptScore W4308139049C2777658017 @default.
• W4308139049 hasConceptScore W4308139049C2779029589 @default.
• W4308139049 hasConceptScore W4308139049C2779318953 @default.
• W4308139049 hasConceptScore W4308139049C2780546910 @default.
• W4308139049 hasConceptScore W4308139049C71315377 @default.
• W4308139049 hasConceptScore W4308139049C71924100 @default.
• W4308139049 hasConceptScore W4308139049C79381400 @default.
• W4308139049 hasConceptScore W4308139049C86803240 @default.
• W4308139049 hasConceptScore W4308139049C94984642 @default.
• W4308139049 hasIssue "Supplement_1" @default.
• W4308139049 hasLocation W43081390491 @default.
• W4308139049 hasLocation W43081390492 @default.
• W4308139049 hasOpenAccess W4308139049 @default.
• W4308139049 hasPrimaryLocation W43081390491 @default.
• W4308139049 hasRelatedWork W1972694889 @default.
• W4308139049 hasRelatedWork W1979660518 @default.
• W4308139049 hasRelatedWork W1996440026 @default.
• W4308139049 hasRelatedWork W2016249479 @default.
• W4308139049 hasRelatedWork W2030158944 @default.
• W4308139049 hasRelatedWork W2088879451 @default.
• W4308139049 hasRelatedWork W2094766549 @default.
• W4308139049 hasRelatedWork W2095045475 @default.
• W4308139049 hasRelatedWork W2594337357 @default.
• W4308139049 hasRelatedWork W4235172593 @default.
• W4308139049 hasVolume "6" @default.
• W4308139049 isParatext "false" @default.
• W4308139049 isRetracted "false" @default.
• W4308139049 workType "article" @default.